US$ 26.76
tirzepatide kwikpen Eli Lilly launched a four-dose, single-patient use device for its injectable obesity drug, (Zepbound). The device gives patients an additional, potentially more convenient option for taking the drug: They can Tirzepatide Now Available in Multi-Dose
Description
Medicare and Medicaid coverage also vary: Medicare: Doesnt typically cover weight-loss prescriptions, but many Part D and Advantage plans are starting to include Zepbound when its used for OSA
British National Formulary [BNF online][]
This route is widely associated with GLP-1 weight management because FDA-approved injectable semaglutide and tirzepatide products are taken once weekly

Proc Natl Acad Sci U S A 117(46):2899229000
